DEALS & SUITS
As part of the deal, Novartis and GlaxoSmithKline
will create a CONSUMER HEALTH CARE JOINT VENTURE.
and associate Simon Bartle. Financing: Guy
O’Keefe and associate Andrew Williams.
(All are in London.) Slaughters represented
Glaxo Wellcome plc on its 2000 merger with
SmithKline Beecham plc and has continued to
work for the combined company.
Cleary Gottlieb Steen & Hamilton:
Antitrust: Patrick Bock, George Cary, Romina
Polley and counsel Kathleen Bradish and Silke
Heinz. (All are in Cologne, Germany, except
for Washington, D.C.-based Cary and Bradish.)
Cleary also represented Glaxo Wellcome on its
merger with SmithKline Beecham.
Niederer Kraft & Frey:
Corporate: Andreas Casutt, Philipp Haas and
senior associate Bertrand Schott and junior
associate Samuel Hochstrasser. Tax: Markus
Kronauer. Real estate: Andreas Vögeli.
Pension and benefits: Senior associate
Laurence Uttinger and associate René Fischer.
Employment: senior associate Valerie Meyer-Bahar. (All are in Zurich.)
For Eli Lilly & Co. (Indianapolis)
General counsel-animal health division C. T.
Newsum, assistant general counsel Joseph
Marxer and counsel-human resources Charles
Weil, Gotshal & Manges:
Corporate: Raymond Gietz, Matthew
Gilroy and associates Kaitlin Descovich,
Joshua Nemser and Megan Pendleton.
Intellectual property: Charan Sandhu,
Elizabeth Weiswasser and associates
Adrienne Baker, Claire Comfort and Rachel
Vigneaux. Tax: Helyn Goldstein and associate
Mark Dundon. Employee benefits and
executive compensation: Amy Rubin
and associate Daniel Birnhak. Real estate:
Samuel Zylberberg and associates Melissa
Meyrowitz and Mallory Owen. (All are in New
York except for Dallas-based Dundon.) Weil has
also represented Eli Lilly on its 2014 acquisition
of German animal health company Lohmann
SE; on its 2012 acquisition of privately held
ChemGen Corp.; and on its 2011 purchase of
Avid Radiopharmaceuticals Inc. for $300 million
Cadwalader, Wickersham & Taft:
Antitrust: Andrew Forman and Charles “Rick”
Rule. (Both are in Washington, D.C.)
Latham & Watkins:
EU competition: Howard Rosenblatt and
counsel Hèctor Armengod. (Both are in
TAKEDA PHARMACEUTICALS NORTH
A jury in Louisiana awarded more than
$9 billion to a New York couple in a
bellwether trial in federal court over
claims that taking diabetes drug Actos
increases the risk of bladder cancer. The
April 7 verdict, the first of 3,000-plus
lawsuits coordinated before U.S. District Judge Rebecca Doherty in Lafayette, La., is bad news for defendants
Takeda Pharmaceuticals USA Inc. and
Eli Lilly & Co. They are represented
by Sara Gourley at Sidley Austin and
Bruce Parker at Venable, who tried the
case together and are jointly overseeing
The companies said in a statement
that the facts didn’t support the outcome and vowed to appeal. (Lilly said
that Takeda has agreed to indemnify it
for losses and expenses related to the
The plaintiff, Terrence Allen, who
began taking Actos in 2006, sued in
2011 shortly after he was diagnosed
with bladder cancer. Six months later,
Takeda changed the Actos label to
reflect new warnings from the U.S.
Food and Drug Administration that
taking the drug for more than a year
might be associated with an increased
risk of the cancer.
Allen looked to W. Mark Lanier of
The Lanier Law Firm to lead at trial;
Richard Arsenault of Neblett, Beard
& Arsenault in Alexandria, La., and
Paul Pennock at New York’s Weitz
& Luxenberg are coleading the MDL
plaintiffs’ steering committee. The trial
also featured sanctions against Takeda
over deleted emails and allegations that
a former Eli Lilly marketing executive
lied in his testimony during trial.
The jury found both companies negligent in failing to warn patients about
the drug’s cancer risks, awarding $1.475
million in compensatory damages.
Takeda was found 75 percent liable and
Lilly 25 percent. Concluding that both
were reckless in marketing the drug,
jurors also awarded $9 billion in punitive damages, $6 billion against Takeda
and $3 billion against Lilly.
At press time a second federal bellwether trial, originally scheduled for
April 14, had been postponed.
—AMANDA BRoNStAD, WIth REBEKAh MINtZER
Patent litigators at Quinn Emanuel
Urquhart & Sullivan nabbed a $283
million plaintiffs verdict on April 24 in
a dustup between two satellite technology companies.
After two weeks of deliberation, a
federal jury in San Diego determined
that Space Systems/Loral LLC infringed
on patents belonging to Quinn Emanuel
client ViaSat Inc. Jurors also found that
SS/L violated nondisclosure agreements
by sharing the satellite technology at
issue with one of ViaSat’s fiercest competitors, Hughes Communications Inc.
(Hughes wasn’t named as a defendant.)
The jury ordered SS/L to pay ViaSat $181
million on the patent infringement claims
and $102 million for breach of contract.
ViaSat and Hughes are designers
of broadband Internet satellites. SS/L,